Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study
PurposeTo retrospectively evaluate the clinical features and prognostic factors of pediatric LCH patients treated in a single center of China.MethodsPediatric LCH cases were treated following the SD-LCH protocol at the Affiliated Provincial Hospital of Shandong First Medical University in Jinan, Chi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1452003/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849774905138085888 |
|---|---|
| author | Yunfeng Lu Liying Liu Qi Wang Bingju Liu Ping Zhao Guotao Guan Yunpeng Dai |
| author_facet | Yunfeng Lu Liying Liu Qi Wang Bingju Liu Ping Zhao Guotao Guan Yunpeng Dai |
| author_sort | Yunfeng Lu |
| collection | DOAJ |
| description | PurposeTo retrospectively evaluate the clinical features and prognostic factors of pediatric LCH patients treated in a single center of China.MethodsPediatric LCH cases were treated following the SD-LCH protocol at the Affiliated Provincial Hospital of Shandong First Medical University in Jinan, China. An analysis was conducted on 82 recently identified LCH cases to retrospectively evaluate the initial symptoms, therapeutic alternatives, and extended results. Follow-ups were conducted until July 31, 2023.ResultsThe median age at diagnosis was 2 (0.25–12) years. 42 (51.2%) were SS-LCH, and 40 (48.8%) were MS-LCH. The most common organ involved was bone (82.9%). Over the 16-year follow-up period, the 5-year EFS and OS rates were 75.2 ± 5% and 90.9 ± 3.3%, respectively. The cumulative reactivation rate was 23.2%. The 5-year EFS rate in SS-LCH and MS-LCH patients were 90.2 ± 4.6% and 58.8 ± 8.3%, and the 5-year OS rate in SS-LCH and MS-LCH patients were 90.2 ± 4.6% and 81.2 ± 6.5%, respectively. The 5-year OS and EFS rate in RO+ LCH and RO− LCH patients were 79.5 ± 7.5%, 53.8 ± 9.6% and 87.5 ± 11.7%, 76.2 ± 14.8%, insignificantly. Multivariate Cox regression showed that liver involvement predicted poor EFS and hematological system involvement was an independent prognostic factor for OS. Detection of the BRAFV600E mutation and targeted therapy significantly improved the prognosis post-2017.ConclusionLiver or hematological system involvement indicates a poor prognosis, and the SD-LCH protocol improves prognosis for pediatric LCH patients. |
| format | Article |
| id | doaj-art-0d4af3cf53ab4f94b3deaf663ae50dc9 |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-0d4af3cf53ab4f94b3deaf663ae50dc92025-08-20T03:01:35ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.14520031452003Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective studyYunfeng LuLiying LiuQi WangBingju LiuPing ZhaoGuotao GuanYunpeng DaiPurposeTo retrospectively evaluate the clinical features and prognostic factors of pediatric LCH patients treated in a single center of China.MethodsPediatric LCH cases were treated following the SD-LCH protocol at the Affiliated Provincial Hospital of Shandong First Medical University in Jinan, China. An analysis was conducted on 82 recently identified LCH cases to retrospectively evaluate the initial symptoms, therapeutic alternatives, and extended results. Follow-ups were conducted until July 31, 2023.ResultsThe median age at diagnosis was 2 (0.25–12) years. 42 (51.2%) were SS-LCH, and 40 (48.8%) were MS-LCH. The most common organ involved was bone (82.9%). Over the 16-year follow-up period, the 5-year EFS and OS rates were 75.2 ± 5% and 90.9 ± 3.3%, respectively. The cumulative reactivation rate was 23.2%. The 5-year EFS rate in SS-LCH and MS-LCH patients were 90.2 ± 4.6% and 58.8 ± 8.3%, and the 5-year OS rate in SS-LCH and MS-LCH patients were 90.2 ± 4.6% and 81.2 ± 6.5%, respectively. The 5-year OS and EFS rate in RO+ LCH and RO− LCH patients were 79.5 ± 7.5%, 53.8 ± 9.6% and 87.5 ± 11.7%, 76.2 ± 14.8%, insignificantly. Multivariate Cox regression showed that liver involvement predicted poor EFS and hematological system involvement was an independent prognostic factor for OS. Detection of the BRAFV600E mutation and targeted therapy significantly improved the prognosis post-2017.ConclusionLiver or hematological system involvement indicates a poor prognosis, and the SD-LCH protocol improves prognosis for pediatric LCH patients.https://www.frontiersin.org/articles/10.3389/fmed.2024.1452003/fullLangerhans cell histiocytosischemotherapypediatric oncologyBRAFV600E inhibitorprognosis |
| spellingShingle | Yunfeng Lu Liying Liu Qi Wang Bingju Liu Ping Zhao Guotao Guan Yunpeng Dai Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study Frontiers in Medicine Langerhans cell histiocytosis chemotherapy pediatric oncology BRAFV600E inhibitor prognosis |
| title | Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study |
| title_full | Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study |
| title_fullStr | Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study |
| title_full_unstemmed | Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study |
| title_short | Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study |
| title_sort | clinical features and prognostic factors of pediatric langerhans cell histiocytosis a single center retrospective study |
| topic | Langerhans cell histiocytosis chemotherapy pediatric oncology BRAFV600E inhibitor prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1452003/full |
| work_keys_str_mv | AT yunfenglu clinicalfeaturesandprognosticfactorsofpediatriclangerhanscellhistiocytosisasinglecenterretrospectivestudy AT liyingliu clinicalfeaturesandprognosticfactorsofpediatriclangerhanscellhistiocytosisasinglecenterretrospectivestudy AT qiwang clinicalfeaturesandprognosticfactorsofpediatriclangerhanscellhistiocytosisasinglecenterretrospectivestudy AT bingjuliu clinicalfeaturesandprognosticfactorsofpediatriclangerhanscellhistiocytosisasinglecenterretrospectivestudy AT pingzhao clinicalfeaturesandprognosticfactorsofpediatriclangerhanscellhistiocytosisasinglecenterretrospectivestudy AT guotaoguan clinicalfeaturesandprognosticfactorsofpediatriclangerhanscellhistiocytosisasinglecenterretrospectivestudy AT yunpengdai clinicalfeaturesandprognosticfactorsofpediatriclangerhanscellhistiocytosisasinglecenterretrospectivestudy |